Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 32% Improvement Relative Risk Mortality (b) 37% Mortality (c) 34% Ñamendys-Silva et al. HCQ for COVID-19 ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 164 patients in Mexico Lower mortality with HCQ (not stat. sig., p=0.19) Ñamendys-Silva et al., Heart & Lung, doi:10.1016/j.hrtlng.2020.10.013 Favors HCQ Favors control
Outcomes of patients with COVID-19 in the Intensive Care Unit in Mexico: A multicenter observational study
Ñamendys-Silva et al., Heart & Lung, doi:10.1016/j.hrtlng.2020.10.013
Ñamendys-Silva et al., Outcomes of patients with COVID-19 in the Intensive Care Unit in Mexico: A multicenter observational study, Heart & Lung, doi:10.1016/j.hrtlng.2020.10.013
Oct 2020   Source   PDF  
  All Studies   Meta
Retrospective 164 ICU patients in Mexico showing 32% lower mortality with HCQ+AZ and 37% lower with CQ.
HCQ+AZ vs. neither HCQ or CQ relative risk RR 0.68, p = 0.03
CQ vs. neither HCQ or CQ relative risk RR 0.63, p = 0.02
HCQ+AZ or CQ vs. neither relative risk RR 0.65, p = 0.006
risk of death, 32.3% lower, RR 0.68, p = 0.18, treatment 24 of 54 (44.4%), control 42 of 64 (65.6%), NNT 4.7, HCQ+AZ vs. neither HCQ or CQ.
risk of death, 37.1% lower, RR 0.63, p = 0.09, treatment 19 of 46 (41.3%), control 42 of 64 (65.6%), NNT 4.1, CQ vs. neither HCQ or CQ.
risk of death, 34.5% lower, RR 0.66, p = 0.006, treatment 43 of 100 (43.0%), control 42 of 64 (65.6%), NNT 4.4, HCQ+AZ or CQ.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ñamendys-Silva et al., 21 Oct 2020, retrospective, database analysis, Mexico, peer-reviewed, mean age 57.3, 18 authors, average treatment delay 7.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Heart & Lung 50 (2021) 28 32 Contents lists available at ScienceDirect Heart & Lung journal homepage: Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study  e Silvio A. Namendys-Silva, MD, MSc, FCCP, FCCMa,h,*, Pedro E. Alvarado-Avila, MDa, a,b a Guillermo Domínguez-Cherit, MD, FCCM , Eduardo Rivero-Sigarroa, MD , nchez-Hurtado, MDc, Alan Gutie rrez-Villasen ~ or, MDd, Luis A. Sa lez, MDd, Heber Rodríguez-Bautista, MDa, Alondra García-Briones, MDd, Juan P. Romero-Gonza stor G. Cruz-Ruiz, MDf, María O. Gonza lez-Herrera, MDg, sar E. Garnica-Camacho, MDe, Ne Ce h h rrez, MD , n, MD , Manuel A. Guerrero-Gutie Francisco J. García-Guille i   L. Canto-Castro, MDj,    Jose D. Salmeron-Gonzalez, MD , Laura Romero-Gutierrez, MDc, Jose Victor H. Cervantes, MDk, on behalf of the Mexico COVID-19 Critical Care Collaborative Group n, Mexico City 14000, Mexico n Salvador Zubira Instituto Nacional de Ciencias Medicas y Nutricio gico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico Tecnolo c Hospital de Especialidades del Centro Medico Nacional Siglo XXI, IMSS, Mexico City, Mexico d Hospital Medica Sur, Mexico City, Mexico e Hospital General de Zona No.1 “Dr. Enrique Von Borstel Labastida”, IMSS, La Paz, Baja California Sur, Mexico f Hospital General de Zona No. 1, “Dr. Demetrio Mayoral Pardo”, IMSS, Oaxaca, Mexico g Hospital General de Zona 1, IMSS, Tlaxcala, Mexico h Instituto Nacional de Cancerología (INCan), Mexico City, Mexico i n, Mexico Hospital General “Dr. Miguel Silva”, Morelia, Michoaca j n, Mexico Unidad Medica de Alta Especialidad "Ignacio García Tellez", IMSS, Merida, Yucata k n, Guanajuato, Mexico Hospital General Regional No. 58, IMSS, Leo a b A R T I C L E I N F O Article History: Received 23 July 2020 Revised 16 October 2020 Accepted 20 October 2020 Available online 21 October 2020 Keywords: COVID-19 SARS-CoV-2 infection Coronavirus Intensive care unit Mexico Outcomes A B S T R A C T Background: As of June 15, 2020, a cumulative total of 7,823,289 confirmed cases of COVID-19 have been reported across 216 countries and territories worldwide. However, there is little information on the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to intensive care units (ICUs) in Latin America. The present study evaluated the clinical characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to ICUs in Mexico. Methods: This was a multicenter observational study that included 164 critically ill patients with laboratoryconfirmed COVID-19 who were admitted to 10 ICUs in Mexico, from April 1 to April 30, 2020. Demographic data, comorbid conditions, clinical presentation, treatment, and outcomes were collected and analyzed. The date of final follow-up was June 4, 2020. Results: A total of 164 patients with severe COVID-19 were included in this study. The mean age of patients was 57.3 years (SD 13.7), 114 (69.5%) were men, and 6.0% were healthcare workers. Comorbid conditions were common in patients with critical COVID-19: 38.4% of patients had hypertension and 32.3% had diabetes. Compared to survivors, nonsurvivors were older and more likely to have diabetes, hypertension or other conditions. Patients presented to the hospital a median of 7 days (IQR 4.5 9) after symptom onset. The most common presenting symptoms were shortness of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop